| 1.82 -0.04 (-2.15%) | 06-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.31 | 1-year : | 2.7 |
| Resists | First : | 1.98 | Second : | 2.31 |
| Pivot price | 1.64  |
|||
| Supports | First : | 1.49 | Second : | 1.19 |
| MAs | MA(5) : | 1.81 |
MA(20) : | 1.57 |
| MA(100) : | 1.42 |
MA(250) : | 1.77 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 83.1 |
D(3) : | 81.7 |
| RSI | RSI(14): 61.5 |
|||
| 52-week | High : | 3.22 | Low : | 0.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ WALD ] has closed below upper band by 31.2%. Bollinger Bands are 52.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.9 - 1.91 | 1.91 - 1.92 |
| Low: | 1.65 - 1.66 | 1.66 - 1.67 |
| Close: | 1.81 - 1.82 | 1.82 - 1.83 |
Waldencast plc operates as a specialized skincare enterprise, delivering sophisticated treatments aimed at improving various dermatological conditions. Its product offerings are crafted to minimize the visual impact of early aging, skin damage, uneven pigmentation, acne, and harm from sun exposure. These solutions are predominantly distributed through professional avenues such as dermatologists, plastic surgeons, medical spas, and other skincare professionals. The company's portfolio encompasses Obagi Medical, which provides groundbreaking skincare products designed to alleviate signs of skin aging, treat issues like dark spots, hyperpigmentation, and fine lines, while simultaneously protecting and enhancing skin's overall tone and texture. Additionally, its Obagi Clinical line features products specifically developed to stave off the initial indicators of skin aging. Founded in 1988, Waldencast plc is based in White Plains, New York.
Mon, 15 Jun 2026
FDA approves Obagi saypha ChIQ filler from Waldencast (NASDAQ: WALD) - Stock Titan
Mon, 15 Jun 2026
Waldencast receives FDA approval for Obagi saypha ChIQ filler - Investing.com
Mon, 15 Jun 2026
FDA approves Obagi cheek-augmentation filler for midface contour issues - Stock Titan
Mon, 01 Jun 2026
Waldencast agrees to sell Obagi Medical for up to $460 million - Investing.com
Mon, 01 Jun 2026
Waldencast plc Announces CEO Changes - marketscreener.com
Tue, 28 Apr 2026
Waldencast plc Exonerated by SEC Following Investigation into Financial Reporting Practices - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Technology
|
|
|
Industry:
Software - Application
|
|
| Shares Out | 118 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 55.6 (%) |
| Held by Institutions | 26.2 (%) |
| Shares Short | 1,090 (K) |
| Shares Short P.Month | 4,220 (K) |
| EPS | -2.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.91 |
| Profit Margin | -84.5 % |
| Operating Margin | -22.5 % |
| Return on Assets (ttm) | -4.8 % |
| Return on Equity (ttm) | -40.4 % |
| Qtrly Rev. Growth | -1.8 % |
| Gross Profit (p.s.) | 1.54 |
| Sales Per Share | 2.3 |
| EBITDA (p.s.) | -0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | 115 (M) |
| PE Ratio | -0.91 |
| PEG Ratio | 0 |
| Price to Book value | 0.46 |
| Price to Sales | 0.79 |
| Price to Cash Flow | -16.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|